CClinicalTrials.gg
CompletedNCT02429557Updated May 5, 2026

Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

A Phase 1 interventional study of Abdominal compression and Sham abdominal compression in Orthostatic Hypotension, Pure Autonomic Failure and Multiple System Atrophy, sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Vanderbilt University Medical Center · Phase 1, Interventional, and Other

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Compression garments have been shown to be effective in the treatment of orthostatic hypotension in autonomic failure patients. The purpose of this study is to determine the hemodynamic mechanisms by which abdominal compression (up to 40 mm Hg) improve the standing blood pressure and orthostatic tolerance in these patients, and to compare them with those of the standard of care midodrine. The investigators will test the hypothesis that abdominal compression will blunt the exaggerated fall in stroke volume and the increase in abdominal vascular volume during head up tilt.

Read the detailed description

Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing) due to severe impairment of the autonomic nervous system. Compression garments such as waist-high stockings and abdominal binders have been shown to improve orthostatic hypotension in these patients. The purpose of this study is to determine the hemodynamic mechanisms by which abdominal compression (up to 40 mm Hg) improve the standing blood pressure and orthostatic tolerance in these patients, and to compare them with those of the standard of care midodrine. The investigators will test the hypothesis that abdominal compression will blunt the exaggerated fall in stroke volume and the increase in abdominal vascular volume during head up tilt. This study will help us better understand the contribution of the abdominal veins to orthostatic hypotension and the mechanisms underlying this non-pharmacological therapeutic approach.

Participants will be studied in a tilt table in two separate days in a randomized, crossover fashion with sham abdominal compression (\~5 mmHg) and active compression (\~40 mmHg).

02

Conditions studied

  • Orthostatic Hypotension
  • Pure Autonomic Failure
  • Multiple System Atrophy
  • Autonomic Failure

Keywords

  • autonomic failure
  • orthostatic hypotension
  • compression garments
  • treatment
03

In context

Hypotension, Orthostatic

155 studies on the registry are indexed under Hypotension, Orthostatic; 34 are open to participants now.

This study's enrollment of 21 is below the median of 30 across 113 interventional studies indexed under Hypotension, Orthostatic.

Browse Hypotension, Orthostatic studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 824 studies on the registry; 164 are open to participants now.

Of its 122 completed or terminated interventional studies of FDA-regulated products, 91 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female patients,
  • between 18-80 yrs.,
  • with neurogenic orthostatic hypotension associated with primary autonomic failure (Parkinson Disease, Multiple System Atrophy and Pure Autonomic Failure). Orthostatic hypotension will be defined as ≥20 mmHg decrease in systolic BP or ≥10 mmHg of diastolic BP within 3 minutes on standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes (Freeman et al., 2011).
  • Patients able and willing to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Significant cardiac, renal or hepatic illness, or with contraindications to administration of pressor agents or external abdominal compression will be excluded.
  • Clinically unstable coronary artery disease, or major cardiovascular or neurological event in the past 6 months, and; other factors which in the investigator's opinion would prevent the subject from completing the protocol including clinically significant abnormalities in clinical, mental or laboratory testing
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Abdominal compression and placebo pill

    Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt

    Other: Abdominal compression · Drug: Placebo pill

  • Sham comparator
    Sham abdominal compression and placebo

    Sham abdominal compression with an inflatable abdominal binder (\~5 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt

    Other: Sham abdominal compression · Drug: Placebo pill

  • Experimental
    Abdominal compression and midodrine

    Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and midodrine 2.5-10 mg PO given 1 hour before the second head up tilt

    Other: Abdominal compression · Drug: midodrine

  • Active comparator
    Sham abdominal compression and midodrine

    Sham abdominal compression with an inflatable abdominal binder (\~5 mmHg) during head up tilt, and midodrine 2.5-10mg PO given 1 hour before the second head up tilt

    Other: Sham abdominal compression · Drug: midodrine

Interventions

  • OtherAbdominal compression

    Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt

    Also known as: abdominal binder

  • OtherSham abdominal compression

    Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt

    Also known as: abdominal binder

  • DrugPlacebo pill

    Placebo pill given 1 hour before the second heat up tilt

  • Drugmidodrine

    Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt

    Also known as: ProAmatine

06

What researchers measure

Primary outcomes

  1. Stroke volume

    Percent change from supine in stroke volume during head up tilt

    Time frame: an average of 15 minutes of head up tilt

Secondary outcomes

  1. Systolic blood pressure

    Change from baseline in systolic blood pressure during head up tilt

    Time frame: an average of 15 minutes of head up tilt

  2. Splanchnic vascular volume

    Percent change from supine in splanchnic vascular volume during head up tilt.

    Time frame: an average of 15 minutes of head up tilt

07

Study locations

1 site
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02429557
Lead sponsor
Vanderbilt University Medical Center
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Luis E Okamoto (Research Assistant Professor, Vanderbilt University Medical Center) — Principal investigator
First posted
Apr 29, 2015
Start date
Apr 2015
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
May 5, 2026

Study contacts

Italo Biaggioni, MD
principal investigator · Vanderbilt University
Luis E Okamoto, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion